Study	Reason for exclusion
Aaes‐Jorgensen 1981	Allocation: random, no further information. Participants: people with paranoid schizophrenia. Interventions: oral cis(z)‐clopenthixol versus oral cis(z)/trans(E)‐clopenthixol, not depot zuclopenthixol.
Gravem 1990	Allocation: random, no further details. Participants: people with schizophrenia or mania. Interventions: combined or separate injections of zuclopenthixol acetate and zuclopenthixol decanoate.
Heikkilä 1981	Allocation: random, no further information. Participants: people with schizophrenia. Interventions: oral zuclopenthixol versus clopenthixol, not depot zuclopenthixol.
Heikkilä 1982	Allocation: random, no further information. Participants: people with schizophrenia. Interventions: oral haloperidol versus zuclopenthixol, not depot zuclopenthixol.
Heikkilä 1992	Allocation: random, no further information. Participants: people with schizophrenia. Interventions: oral haloperidol verus zuclopenthixol, not depot zuclopenthixol.
Kabes 1981	Allocation: not randomised, case series.
Kingstone 1970	Allocation: random, on admission assigned to a number allocated to a bottle. Participants: those with schizophrenia. Interventions: oral clopenthixol versus chlorpromazine, not depot zuclopenthixol.
Lublin 1991	Allocation: randomised, crossover. Participants: those with schizophrenia and tardive dyskinesia. Interventions: oral haloperidol versus zuclopenthixol, not depot zuclopenthixol.
Peacock 1996	Allocation: consecutively on admission. Participants: those with schizophrenia. Interventions: clozapine, zuclopenthixol or flupenthixol, not depot zuclopenthixol.
Remvig 1987	Allocation: random, no further information. Participants: people with schizophrenia. Interventions: oral zuclopenthixol versus perphenazine, not depot zuclopenthixol.
Serafetinides 1972	Allocation: random, no further information. Participants: those with schizophrenia. Interventions: oral clopenthixol, chlorpromazine, haloperidol or placebo, not depot zuclopenthixol.
Simpson 1972	Allocation: unclear. Participants: people with schizophrenia. Interventions: oral clopenthixol, not depot zuclopenthixol..
Viala 1988	Allocation: unclear. Participants: people with schizophrenia. Interventions: zuclopenthixol decanoate versus fluphenazine decanoate Outcomes: plasma concentration levels, no clinical outcomes.
Vinar 1967	Allocation: unclear. Participants: two groups of people with schizophrenia. Interventions: oral zuclopenthixol, unclear if different doses, not depot zuclopenthixol.
Walker 1983	Allocation: random ‐ no further details. Participants: those with schizophrenia. Interventions: zuclopenthixol decanoate versus fluphenazine decanoate. Outcomes: six people excluded from analysis and it is unclear from which groups they were excluded. Further information is being sought from trialists.